Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 5/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 18/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 15/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880149 | 1.00 | FGFR4 (0.49) | FGFR4FGFR3FGFR2FGFR1 | |
| SCHEMBL22348762 | 0.91 | FGFR4 (0.49) | FGFR4FGFR3FGFR2FGFR1 | |
| SCHEMBL30880141 | 0.91 | FGFR4 (0.49) | FGFR4FGFR3FGFR2FGFR1 | |
| SCHEMBL22348692 | 0.91 | FGFR3 (0.49) | FGFR4FGFR3FGFR2FGFR1 | |
| SCHEMBL30880129 | 0.91 | FGFR3 (0.49) | FGFR4FGFR3FGFR2FGFR1 | |
| SCHEMBL22348685 | 0.90 | FGFR4 (0.50) | FGFR4FGFR3FGFR2FGFR1 | |
| SCHEMBL30880137 | 0.90 | FGFR4 (0.50) | FGFR4FGFR3FGFR2FGFR1 | |
| SCHEMBL30880126 | 0.90 | FGFR3 (0.50) | FGFR4FGFR3FGFR2FGFR1 | |
| SCHEMBL22348763 | 0.90 | FGFR4 (0.48) | FGFR4FGFR3FGFR2FGFR1 | |
| SCHEMBL30880128 | 0.90 | FGFR4 (0.48) | FGFR4FGFR3FGFR2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113795256-B | FGFR inhibitors for treatment of cancer | 布里奇恩生物科学公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-3923947-A1 | FGFR INHIBITORS FOR THE TREATMENT OF CANCER | Bridgene Biosciences, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113795256-A | FGFR inhibitors for the treatment of cancer | 布里奇恩生物科学公司 | 2021-12-14 | — | — | CN | disclosed |
| WO-2020168237-A1 | FGFR INHIBITORS FOR THE TREATMENT OF CANCER | BRIDGENE BIOSCIENCES, INC. (US) | 2020-08-20 | — | — | WO | disclosed |